Stocks of Abbott Laboratories (NYSE:ABT) traded higher last session on Wall Street, down -0.58% to $104.88.
ABT stock price is now -0.21% away from the 50-day moving average and -1.29% away from the 200-day moving average. The market capitalization of the company currently stands at $182.45B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $121, Goldman recently initiated with Buy rating for Abbott Laboratories (NYSE: ABT). , while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’
In other news, Funck, Jr. Robert E., EXECUTIVE VICE PRESIDENT sold 10,097 shares of the company’s stock on May 10 ’24. The stock was sold for $1,055,819 at an average price of $104.57. Upon completion of the transaction, the EXECUTIVE VICE PRESIDENT now directly owns 211,341 shares in the company, valued at $22.17 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 07 ’24, EXECUTIVE VICE PRESIDENT Earnhardt Lisa D sold 22,852 shares of the business’s stock. A total of $2,428,119 was realized by selling the stock at an average price of $106.25. This leaves the insider owning 61,462 shares of the company worth $6.45 million. A total of 0.72% of the company’s stock is owned by insiders.
During the past 12 months, Abbott Laboratories has had a low of $89.67 and a high of $121.64. As of last week, the company has a debt-to-equity ratio of 0.38, a current ratio of 1.60, and a quick ratio of 1.11. According to the stock market information, the enterprise value for the company is $190739857408, which is based on a 32.67 price-to-earnings ratio, a 4.03 price-to-earnings-growth ratio, and a beta of 0.72. The fifty day moving average price for ABT is $105.0162 and a two-hundred day moving average price translates $106.26855 for the stock.
The latest earnings results from Abbott Laboratories (NYSE: ABT) was released for 2024-03-31. The net profit margin was 13.91% and return on equity was 14.80% for ABT. The company reported revenue of $9.96 billion for the quarter, compared to $9.75 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.23 percent.
